The Battle Between Tumors and Complement
The complement system, as an important component of the body’s immune system, plays a key role in tumor development and therapy. Tumor immunomodulation by the complement system has a dual role inRead More…
The complement system, as an important component of the body’s immune system, plays a key role in tumor development and therapy. Tumor immunomodulation by the complement system has a dual role inRead More…
The complement system is an important part of the innate and adaptive immune system. When activated, it participates in the body’s defense response and immune regulation, including enhancing antibody response, possessing immuneRead More…
On February 17, 2023, Apellis announced the FDA approval of Pegcetacoplan, a complement C3 inhibitor, as the first molecularly targeted drug for the treatment of dry AMD or geographic atrophy. This approvalRead More…
On November 3, 2022, Iveric Bio announced that it had submitted the first part of the “rolling review” for the new drug application (NDA) of avacincaptad pegol (ACP, also known as Zimura)Read More…
Novartis recently announced that its new drug iptacopan has achieved positive results in a Phase 3 clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with patients’ hemoglobin levels increasing significantlyRead More…
The complement system, also known as the complement cascade, is a crucial component of both the innate and the adaptive immune systems, which can assist or supplement antibodies and phagocytes to clearRead More…
On April 28, AstraZeneca released news that its subsidiary Alexion’s new drug Ultomiris (Ravulizumab) was approved by the FDA for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) adultRead More…
Targeted therapy is the strategies employed by of most current tumor drugs, but in fact many of them have poor selectivity and certain off-target toxicity. Correspondingly, an approach that becomes increasingly prominentRead More…
On February 4, 2022, Sanofi announced that its complement C1s antibody Sutimlimab was approved by the FDA for the treatment of cold agglutinin disease (CAD) under the trade name Enjaymo. Sutimlimab isRead More…